Animal Model for Prodromal Parkinson's Disease.
Parkinson’s disease
alpha synuclein
animal model
prodromal
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
13 Mar 2020
13 Mar 2020
Historique:
received:
04
02
2020
revised:
10
03
2020
accepted:
11
03
2020
entrez:
19
3
2020
pubmed:
19
3
2020
medline:
2
12
2020
Statut:
epublish
Résumé
Parkinson's disease (PD) is characterized by the loss of dopaminergic neurons in the substantia nigra and subsequent motor symptoms, but various non-motor symptoms (NMS) often precede motor symptoms. Recently, NMS have attracted much attention as a clue for identifying patients in a prodromal stage of PD, which is an excellent point at which to administer disease-modifying therapies (DMTs). These prodromal symptoms include olfactory loss, constipation, and sleep disorders, especially rapid eye movement sleep behavior disorder (RBD), all of which are also important for elucidating the mechanisms of the initiation and progression of the disease. For the development of DMTs, an animal model that reproduces the prodromal stage of PD is also needed. There have been various mammalian models reported, including toxin-based, genetic, and alpha synuclein propagation models. In this article, we review the animal models that exhibit NMS as prodromal symptoms and also discuss an appropriate prodromal model and its importance for the development of DMT of PD.
Identifiants
pubmed: 32183024
pii: ijms21061961
doi: 10.3390/ijms21061961
pmc: PMC7139491
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Agency for Medical Research and Development
ID : R.T. JP18dm0207020 and 19dm0207070
Références
J Neurosci. 2006 Apr 12;26(15):3942-50
pubmed: 16611810
Science. 2012 Nov 16;338(6109):949-53
pubmed: 23161999
Lancet. 2004 Sep 25-Oct 1;364(9440):1167-9
pubmed: 15451224
Neurobiol Dis. 2018 Apr;112:106-118
pubmed: 29341898
Neurobiol Dis. 2009 Oct;36(1):96-102
pubmed: 19595768
J Neurosci Res. 2002 Jun 1;68(5):568-78
pubmed: 12111846
Brain. 2017 Feb;140(2):414-428
pubmed: 28007991
Acta Neuropathol. 2010 Jun;119(6):689-702
pubmed: 20306269
Ann Neurol. 2008 Nov;64(5):485-91
pubmed: 19067353
Neurology. 1995 Apr;45(4):709-12
pubmed: 7723959
Neurosci Res. 2012 Jun;73(2):173-7
pubmed: 22475625
Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8968-73
pubmed: 12084935
Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):E4016-25
pubmed: 24082145
Neurotox Res. 2007 Apr;11(3-4):151-67
pubmed: 17449457
Neurotherapeutics. 2012 Apr;9(2):297-314
pubmed: 22350713
Trends Neurosci. 2014 May;37(5):279-88
pubmed: 24673896
PLoS One. 2015 Mar 23;10(3):e0119928
pubmed: 25799501
Parkinsons Dis. 2014;2014:852965
pubmed: 25610706
Neurobiol Dis. 2014 Feb;62:193-207
pubmed: 24121116
Brain. 2019 Jan 1;143(1):249-265
pubmed: 31816026
Science. 2003 Oct 31;302(5646):841
pubmed: 14593171
Exp Neurol. 2013 Feb;240:44-56
pubmed: 23153578
J Exp Med. 2016 Aug 22;213(9):1759-78
pubmed: 27503075
Front Cell Neurosci. 2014 Dec 01;8:383
pubmed: 25520618
Mov Disord. 2004 Jun;19(6):687-92
pubmed: 15197709
Lancet. 2004 Sep 25-Oct 1;364(9440):1169-71
pubmed: 15451225
Parkinsons Dis. 2011;2011:143547
pubmed: 21687804
Transl Neurodegener. 2019 Feb 6;8:5
pubmed: 30774946
Neurobiol Dis. 2017 Sep;105:179-193
pubmed: 28576705
Exp Neurol. 2014 Jun;256:105-16
pubmed: 23360802
Lancet Neurol. 2013 May;12(5):443-53
pubmed: 23562390
Mol Psychiatry. 2019 Nov 22;:
pubmed: 31758091
Neurosci Lett. 2006 Mar 20;396(1):67-72
pubmed: 16330147
Ann N Y Acad Sci. 2009 Jul;1170:629-36
pubmed: 19686204
Nature. 1997 Aug 28;388(6645):839-40
pubmed: 9278044
Exp Neurol. 2009 Jul;218(1):154-61
pubmed: 19409896
Nat Genet. 2009 Dec;41(12):1308-12
pubmed: 19915575
Neuron. 2019 Aug 21;103(4):627-641.e7
pubmed: 31255487
Exp Neurol. 2007 Sep;207(1):4-12
pubmed: 17586496
Neurobiol Aging. 2003 Mar-Apr;24(2):197-211
pubmed: 12498954
Mol Neurodegener. 2018 May 11;13(1):21
pubmed: 29751824
Exp Neurol. 2009 Oct;219(2):574-82
pubmed: 19635479
Eur J Neurosci. 2008 Jul;28(2):247-56
pubmed: 18702696
Nat Commun. 2018 Feb 5;9(1):504
pubmed: 29402935
Acta Neuropathol. 2018 Jan;135(1):65-83
pubmed: 29209768
Lancet. 1989 Jun 3;1(8649):1269
pubmed: 2566813
Nat Genet. 2009 Dec;41(12):1303-7
pubmed: 19915576
Neuron. 2002 May 16;34(4):521-33
pubmed: 12062037
Neurotoxicology. 2015 Jan;46:101-16
pubmed: 25514659
J Biol Chem. 2011 Oct 7;286(40):35104-18
pubmed: 21846727
Brain. 1991 Oct;114 ( Pt 5):2283-301
pubmed: 1933245
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S17-9
pubmed: 24262174
Sleep Med. 2007 Jan;8(1):60-4
pubmed: 17157062
Nat Med. 2008 May;14(5):501-3
pubmed: 18391963
Neurology. 2009 Nov 24;73(21):1752-8
pubmed: 19933976
Brain. 2013 Feb;136(Pt 2):412-32
pubmed: 23413261
PLoS One. 2013 Jul 30;8(7):e70249
pubmed: 23936174
Neurogastroenterol Motil. 2009 Feb;21(2):215-22
pubmed: 19077145
Front Pharmacol. 2019 Nov 27;10:1414
pubmed: 31827439
Sleep. 2011 Aug 01;34(8):1119-25
pubmed: 21804674
Hum Mol Genet. 2010 May 1;19(9):1633-50
pubmed: 20106867
Neurobiol Dis. 2012 Jun;46(3):527-52
pubmed: 22192366
Nat Rev Neurol. 2016 Oct 27;12(11):622-634
pubmed: 27786242
Nat Med. 2008 May;14(5):504-6
pubmed: 18391962
Acta Neuropathol. 1988;76(3):217-221
pubmed: 2850698
J Neural Transm (Vienna). 2015 Oct;122(10):1429-40
pubmed: 25976432
Mov Disord. 2019 Oct;34(10):1464-1470
pubmed: 31412427
Nat Clin Pract Neurol. 2008 May;4(5):254-66
pubmed: 18398415
J Neurol. 2015 Jun;262(6):1568-78
pubmed: 25929658
Neurosci Lett. 2020 Jan 18;716:134651
pubmed: 31783082
Nat Neurosci. 2000 Dec;3(12):1301-6
pubmed: 11100151
Hum Mol Genet. 2019 Jun 1;28(11):1894-1904
pubmed: 30689867